The Sigma1 Protein As a Target for the Non-Genomic Effects of Neuro(Active)Steroids: Molecular, Physiological, and Behavioral Aspects François P

Total Page:16

File Type:pdf, Size:1020Kb

The Sigma1 Protein As a Target for the Non-Genomic Effects of Neuro(Active)Steroids: Molecular, Physiological, and Behavioral Aspects François P J Pharmacol Sci 100, 93 – 118 (2006) Journal of Pharmacological Sciences ©2006 The Japanese Pharmacological Society Critical Review The Sigma1 Protein as a Target for the Non-genomic Effects of Neuro(active)steroids: Molecular, Physiological, and Behavioral Aspects François P. Monnet1 and Tangui Maurice2,* 1Unité 705 de l’Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 7157 du Centre National de la Recherche Scientifique, Université de Paris V et VII, Hôpital Lariboisière-Fernand Widal, 2, rue Ambroise Paré, 75475 Paris cedex 10, France 2Unité 710 de l’Institut National de la Santé et de la Recherche Médicale, Ecole Pratique des Hautes Etudes, Université de Montpellier II, cc 105, place Eugène Bataillon, 34095 Montpellier cedex 5, France Received December 15, 2005 Abstract. Steroids synthesized in the periphery or de novo in the brain, so called ‘neuro- steroids’, exert both genomic and nongenomic actions on neurotransmission systems. Through rapid modulatory effects on neurotransmitter receptors, they influence inhibitory and excitatory neurotransmission. In particular, progesterone derivatives like 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) are positive allosteric modulators of the γ-aminobutyric acid type A (GABAA) receptor and therefore act as inhibitory steroids, while pregnenolone sulphate (PREGS) and dehydroepiandrosterone sulphate (DHEAS) are negative modulators of the GABAA receptor and positive modulators of the N-methyl-D-aspartate (NMDA) receptor, therefore acting as excitatory neurosteroids. Some steroids also interact with atypical proteins, the sigma (σ) receptors. Recent studies particularly demonstrated that the σ1 receptor contributes effectively to their pharmaco- logical actions. The present article will review the data demonstrating that the σ1 receptor binds neurosteroids in physiological conditions. The physiological relevance of this interaction will be analyzed and the impact on physiopathological outcomes in memory and drug addiction will be illustrated. We will particularly highlight, first, the importance of the σ1-receptor activation by PREGS and DHEAS which may contribute to their modulatory effect on calcium homeostasis and, second, the importance of the steroid tonus in the pharmacological development of selective σ1 drugs. Keywords: neuro(active)steroid, sigma1 receptor, neurotransmission, neuronal plasticity, learning and memory 1. Neurosteroids and σ receptors ......................................................94 3. Physiological aspects of σ receptor and neurosteroid functions ... 101 1.1. Neuro(active)steroids biosyntheses 3.1. Does σ binding protein interfere with (neuro)steroid synthesis? 1.2. Neurosteroids play a role in the excitatory/inhibitory balance 3.2. Neurosteroids and σ drugs share modulatory functions at both in the brain pre- and post-synaptic levels 1.3. The σ receptor, an atypical neuromodulatory system 3.2.1. Do neurosteroids and σ drugs exhibit similar effects 1.4. The σ1 receptor acts as an intracellular amplifier of signal on neuronal firing? transduction system involved in the formation 3.2.2. Neurosteroids and σ drugs affect neuronal excitability and recomposition of membrane lipid microdomains induced by the NMDA receptor 2. Neurosteroids and σ drugs apparently share the same binding sites 3.2.3. Neurosteroids and σ drugs may have a similar impact ...............................................................................................98 on neurotransmitter release 2.1. Steroids and neurosteroids bind both σ1 and σ2 sites 4. Behavioral effects of σ-receptor ligands and neurosteroids....... 105 in the central nervous system 4.1. Neurosteroids and σ drugs affect learning and memory 2.2. Steroids and neurosteroids bind both σ1 and σ2 sites processes in peripheral tissues 4.1.1. Pro-mnesic effects of neurosteroids and σ drugs 2.3. Do neurosteroids also bind atypical σ-receptor subtypes? 4.1.2. Anti-amnesic effects in cholinergic models of amnesia 4.1.3. Anti-amnesic effects in NMDA-receptor-dependent amnesia *Corresponding author. [email protected] 4.1.4. Anti-amnesic effects of neurosteroids and σ drugs Published online in J-STAGE: February 11, 2006 during aging DOI: 10.1254/jphs.CR0050032 4.2. Neurosteroids and σ drugs may influence abused drug intake 4.3. Cross-influences between neurosteroids and σ receptor Invited article 5. Conclusions................................................................................ 111 93 94 FP Monnet and T Maurice 1. Neurosteroids and σ receptors P450 side-chain cleavage (P450scc) enzyme, a conver- sion that constitutes the rate-limiting step in steroido- The first description of a biological activity for genesis (3). PREG could then be metabolized into steroids, the anesthetic properties of progesterone, dates progesterone by a 3β-hydroxysteroid dehydrogenase from the 1941 report by Selye (1). The subsequent (3βHSD). PREG could also be converted into 17α- characterization of central effects exerted by steroid hydroxypregnenolone by a cytochrome P450c17, which hormones, and their syntheses in the nervous system leads to dehydroepiandrosterone (DHEA) and andros- defining the concept of neurosteroids, dates from 25 tenedione by the scission of the c17,20 bond. These years ago. Neuroactive steroids include both steroids two pathways lead to the formation of pregnanes and from the periphery, which are transported through the androstanes steroids, respectively, and the most highly blood-brain-barrier and act within the brain, and locally expressed steroids in the brain are PREG, DHEA, their synthesized neurosteroids. Their physiological actions, sulphate esters (PREGS and DHEAS), progesterone, demonstrated from embryogenesis through adult life, and 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) involve genomic actions, mediated by steroid receptors among the tetrahydroprogesterone isomers. The expres- translocating into the nucleus, and non-genomic neuro- sion, distribution, and ontogeny of most of the modulatory actions affecting directly several ion chan- steroidogenic enzymes and synthesized steroids have nels, neurotransmitter receptors, and second messenger been determined in the brain (3) and similarities with systems. The syntheses and effects of these neuro the peripheral synthetic pathway were identified. Most (active)steroids and their physiopathological conse- of the enzymes, including P450scc, P450c17, 3βHSD, quences have been extensively reviewed (2 – 13). In and 5α-reductase, which convert PREG into progester- particular, the mechanisms by which they act as allos- one, are co-expressed in limbic structures such as the teric modulators of the γ-aminobutyric acid type A hippocampus, caudate putamen, hypothalamic nuclei, (GABAA) receptor and N-methyl-D-aspartate (NMDA) cortex, olfactory bulb, and cerebellum (3). type of glutamate receptor is now extensively docu- Various physiological and pathological conditions are mented. They also affect acetylcholine systems through associated with changes in neurosteroid levels. Neuro- direct and indirect actions. More atypical is their re- steroid syntheses significantly vary during acute and ported interaction with the sigma1 (σ1) receptors (14 – chronic stress, pregnancy, neural development, and 17). In the present review article, we will detail the normal and pathological aging. In humans, plasma levels molecular, physiological, and behavioral data support- of DHEAS decline with age (22, 23). In rodents, ing the concepts that not only certain neurosteroids significant decreases of PREGS levels in aged Sprague interact at physiological concentration with σ1 receptors Dawley rat brain were reported to correlate with and may represent their endogenous ligands but also that impaired memory functions (24). Aged C57BL/6 mice the neurosteroid/σ1 receptor interaction may present or senescence-accelerated (SAM) mice also show major physiopathological consequences. We will parti- important decreases in the brain levels of PREG and cularly illustrate their involvement in memory processes PREGS (PREG/S), DHEA and DHEAS (DHEA/S), and vulnerability to drug addiction. or progesterone (25, 26). Moreover, brain structural abnormalities related to Alzheimer’s disease, like both 1.1. Neuro(active)steroids biosyntheses β-amyloid deposits and neurofibrillary tangles, which Steroids are synthesised in adrenal glands and gonads result from the aggregation of pathologic τ proteins, and exert their hormonal effects in peripheral organs and affect brain neurosteroid levels. Brown et al. (27) the brain. The identification of pools of steroids whose reported that β1–42-amyloid protein increased DHEA levels were higher in the brain than in plasma, indepen- levels in a human glia-derived cell line, after a 24 h dently of peripheral sources led to the concept of ‘neuro- application, a synthesis interpreted as a neuroprotective steroids’ (18 – 20). These neurosteroids are synthesized response to the β-amyloid-induced toxicity. Neuro- locally in the mitochondria of glial cells, such as oligo- steroid levels were measured in two in vivo models of dendrocytes and astrocytes, and neurons. Fifteen days β-amyloid toxicity, the intracerebroventricular injection after removing the sources of circulating steroids by of aggregated β25–35-amyloid peptide in mice and the adrenalectomy and gonadectomy (AdX/CX) in rodents, chronic infusion during a 2-week period of β1–40-amyloid no difference in the brain neurosteroid levels could be protein in rats. Decreased
Recommended publications
  • The Pharmacologist 2 0 0 6 December
    Vol. 48 Number 4 The Pharmacologist 2 0 0 6 December 2006 YEAR IN REVIEW The Presidential Torch is passed from James E. Experimental Biology 2006 in San Francisco Barrett to Elaine Sanders-Bush ASPET Members attend the 15th World Congress in China Young Scientists at EB 2006 ASPET Awards Winners at EB 2006 Inside this Issue: ASPET Election Online EB ’07 Program Grid Neuropharmacology Division Mixer at SFN 2006 New England Chapter Meeting Summary SEPS Meeting Summary and Abstracts MAPS Meeting Summary and Abstracts Call for Late-Breaking Abstracts for EB‘07 A Publication of the American Society for 121 Pharmacology and Experimental Therapeutics - ASPET Volume 48 Number 4, 2006 The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. The Editor PHARMACOLOGIST Suzie Thompson EDITORIAL ADVISORY BOARD Bryan F. Cox, Ph.D. News Ronald N. Hines, Ph.D. Terrence J. Monks, Ph.D. 2006 Year in Review page 123 COUNCIL . President Contributors for 2006 . page 124 Elaine Sanders-Bush, Ph.D. Election 2007 . President-Elect page 126 Kenneth P. Minneman, Ph.D. EB 2007 Program Grid . page 130 Past President James E. Barrett, Ph.D. Features Secretary/Treasurer Lynn Wecker, Ph.D. Secretary/Treasurer-Elect Journals . Annette E. Fleckenstein, Ph.D. page 132 Past Secretary/Treasurer Public Affairs & Government Relations . page 134 Patricia K. Sonsalla, Ph.D. Division News Councilors Bryan F. Cox, Ph.D. Division for Neuropharmacology . page 136 Ronald N. Hines, Ph.D. Centennial Update . Terrence J. Monks, Ph.D. page 137 Chair, Board of Publications Trustees Members in the News .
    [Show full text]
  • A Role for Sigma Receptors in Stimulant Self Administration and Addiction
    Pharmaceuticals 2011, 4, 880-914; doi:10.3390/ph4060880 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review A Role for Sigma Receptors in Stimulant Self Administration and Addiction Jonathan L. Katz *, Tsung-Ping Su, Takato Hiranita, Teruo Hayashi, Gianluigi Tanda, Theresa Kopajtic and Shang-Yi Tsai Psychobiology and Cellular Pathobiology Sections, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, 21224, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]. Received: 16 May 2011; in revised form: 11 June 2011 / Accepted: 13 June 2011 / Published: 17 June 2011 Abstract: Sigma1 receptors (σ1Rs) represent a structurally unique class of intracellular proteins that function as chaperones. σ1Rs translocate from the mitochondria-associated membrane to the cell nucleus or cell membrane, and through protein-protein interactions influence several targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins. Several studies have demonstrated that σR antagonists block stimulant-induced behavioral effects, including ambulatory activity, sensitization, and acute toxicities. Curiously, the effects of stimulants have been blocked by σR antagonists tested under place-conditioning but not self-administration procedures, indicating fundamental differences in the mechanisms underlying these two effects. The self administration of σR agonists has been found in subjects previously trained to self administer cocaine. The reinforcing effects of the σR agonists were blocked by σR antagonists. Additionally, σR agonists were found to increase dopamine concentrations in the nucleus accumbens shell, a brain region considered important for the reinforcing effects of abused drugs.
    [Show full text]
  • Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors
    1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed.
    [Show full text]
  • Basic Quant GCMS
    Harris County Institute of Forensic Sciences Section: Toxicology Approved By: Toxicology Manager Document Type: GC & GC/MS Procedure No.: TOX07.3005 Title: Quantitation of basic drugs by gas chromatography / mass spectrometry Rev.:15 1.0 Purpose 1.1 This document describes the procedures used by the Toxicology Laboratory to quantitate basic drugs using gas chromatography/mass spectrometry. 1.2 Biological specimens are basified to the moderately alkaline pH 9 at which basic compounds are in an unionized form and are soluble in an organic solvent. After liquid/liquid extraction, the organic layer is separated and the compound X is back extracted into 2 N HCl. The acid layer is then made alkaline and compound X is re-extracted into an organic solvent. 2.0 Scope 2.1 The assay is appropriate for quantitation of any basic compound (X) in blood including serum and plasma, urine, bile, stomach contents or tissue homogenates. 3.0 Definitions and Abbreviations 3.1 No method-specific or non-standard terms are used in this procedure. 4.0 Materials 4.1 Instruments and Equipment 4.1.1 13 x 100 mm screw top tubes and caps 4.1.2 Mixer 4.1.3 Rocker 4.1.4 Centrifuge 4.1.5 Transfer pipettes 4.1.6 Autosampler vials and rubber septum caps 4.1.7 Autosampler vial inserts 4.1.8 Vial crimper 4.1.9 100uL syringe 4.1.10 GC/MS Uncontrolled4.2 Reagents Copy 4.2.1 Ammonium Hydroxide Reagent Grade 4.2.2 n-Butyl chloride (chlorobutane) HPLC Grade 4.2.3 Saturated Sodium Borate Buffer, pH 9.3 A.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0171347 A1 Matsumoto (43) Pub
    US 2003.0171347A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0171347 A1 Matsumoto (43) Pub. Date: Sep. 11, 2003 (54) SIGMA RECEPTOR ANTAGONISTS HAVING Publication Classification ANT-COCANE PROPERTIES AND USES THEREOF (51) Int. Cl." ......................... A61K 31/55; A61K 31/33; A61K 31/397; A61K 31/445; (76) Inventor: Rae R. Matsumoto, Edmond, OK (US) A61K 31/40; A61K 31/137 (52) U.S. Cl. .............. 514/183; 514/210.01; 514/217.12; Correspondence Address: 514/317; 514/408; 514/649 DUNLAP, CODDING & ROGERS PC. PO BOX 16370 OKLAHOMA CITY, OK 73114 (US) (57) ABSTRACT (21) Appl. No.: 10/178,859 The present invention relates to novel Sigma receptor antagonist compounds that have anti-cocaine properties. (22) Filed: Jun. 21, 2002 These Sigma receptor antagonists are useful in the treatment Related U.S. Application Data of cocaine overdose and addiction as well as movement disorders. The Sigma receptor antagonists of the present (63) Continuation of application No. 09/715,911, filed on invention may also be used in the treatment of neurological, Nov. 17, 2000, now abandoned, which is a continu psychiatric, gastrointestinal, cardiovascular, endocrine and ation of application No. 09/316,877, filed on May 21, immune System disorders as well as for imaging procedures. 1999, now abandoned. The present invention also relates to novel pharmaceutical compounds incorporating Sigma receptor antagonists which (60) Provisional application No. 60/086,550, filed on May can be used to treat overdose and addiction resulting from 21, 1998. the use of cocaine and/or other drugs of abuse.
    [Show full text]
  • Effect of Isopregnanolone on Rapid Tolerance to the Anxiolytic Effect of Ethanol Influência Da Isopregnenolona Na Tolerância R
    18 ORIGINAL ARTICLE Effect of isopregnanolone on rapid tolerance to the anxiolytic effect of ethanol Influência da isopregnenolona na tolerância rápida ao efeito ansiolítico do etanol Thaize Debatin,1 Adriana Dias Elpo Barbosa2 Original version accepted in Portuguese Abstract Objective: It has been shown that neurosteroids can either block or stimulate the development of chronic and rapid tolerance to the incoordination and hypothermia caused by ethanol consumption. The aim of the present study was to investigate the influence of isopregnanolone on the development of rapid tolerance to the anxiolytic effect of ethanol in mice. Method: Male Swiss mice were pretreated with isopregnanolone (0.05, 0.10 or 0.20 mg/kg) 30 min before administration of ethanol (1.5 g/kg). Twenty-four hours later, all animals we tested using the plus-maze apparatus. The first experiment defined the doses of ethanol that did or did not induce rapid tolerance to the anxiolytic effect of ethanol. In the second, the influence of pretreatment of mice with isopregnanolone (0.05, 0.10 or 0.20 mg/kg) on rapid tolerance to ethanol (1.5 g/kg) was studied. Conclusions: The results show that pretreatment with isopregnanolone interfered with the development of rapid tolerance to the anxiolytic effect of ethanol. Keywords: Ethanol; Drug tolerance; Anti-anxiety agents; Mice; Alcoholism Resumo Objetivo: Estudos prévios têm mostrado que os neuroesteróides podem bloquear ou estimular o desenvolvimento da tolerância rápida e crônica aos efeitos de incoordenação e hipotermia produzidos pelo etanol. O objetivo do presente estudo foi investigar a influência da isopregnenolona sobre o desenvolvimento da tolerância rápida ao efeito ansiolítico do etanol em camundongos.
    [Show full text]
  • Epipregnanolone and a Novel Synthetic Neuroactive Steroid Reduce Reduce Alcohol Self- Administration in Rats
    University of Texas at El Paso From the SelectedWorks of Laura Elena O'Dell 2005 Epipregnanolone and a novel synthetic neuroactive steroid reduce reduce alcohol self- administration in rats. Laura O'Dell, University of Texas at El Paso Available at: https://works.bepress.com/laura_odell/23/ Pharmacology, Biochemistry and Behavior 81 (2005) 543 – 550 www.elsevier.com/locate/pharmbiochembeh Epipregnanolone and a novel synthetic neuroactive steroid reduce alcohol self-administration in rats L.E. O’Della,b, R.H. Purdya,c,d, D.F. Coveye, H.N. Richardsona, M. Robertoa, G.F. Kooba,* aDepartment of Neuropharmacology, The Scripps Research Institute, CVN-7, 10550 North Torrey Pines Rd., La Jolla, CA, 92037, USA bDepartment of Psychology, The University of Texas at El Paso, El Paso, TX, USA cDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA dDepartment of Veterans Affairs Medical Center and Veterans Medical Research Foundation, San Diego, CA, USA eDepartment of Molecular Biology and Pharmacology, Washington University School of Medicine, St Louis, MO, USA Received 6 September 2004; received in revised form 14 March 2005; accepted 31 March 2005 Available online 9 June 2005 Abstract This study was designed to compare the effects of several neuroactive steroids with varying patterns of modulation of g-aminobutyric acid (GABA)A and NMDA receptors on operant self-administration of ethanol or water. Once stable responding for 10% (w/v) ethanol was achieved, separate test sessions were conducted in which male Wistar rats were allowed to self-administer ethanol or water following pre-treatment with vehicle or one of the following neuroactive steroids: (3h,5h)-3-hydroxypregnan-20-one (epipregnanolone; 5, 10, 20 mg/kg; n =12), (3a,5h)-20-oxo-pregnane-3-carboxylic acid (PCA; 10, 20, 30 mg/kg; n =10), (3a,5h)-3-hydroxypregnan-20-one hemisuccinate (pregnanolone hemisuccinate; 5, 10, 20 mg/kg; n =12) and (3a,5a)-3-hydroxyandrostan-17-one hemisuccinate (androsterone hemisuccinate; 5, 10, 20 mg/kg; n =11).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Epipregnanolone Item No. 34295 CAS Registry No.: 128-21-2 O Formal Name: (5β)-3β-hydroxy-pregnan-20-one Synonyms: NSC 21450, 5β-Pregnan-3β-ol-20-one MF: C21H34O2 FW: 318.5 H Purity: ≥98% H H Supplied as: A solid Storage: -20°C HO Stability: ≥2 years H Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Epipregnanolone is supplied as a solid. A stock solution may be made by dissolving the epipregnanolone in the solvent of choice, which should be purged with an inert gas. Epipregnanolone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of epipregnanolone in ethanol is approximately 5 mg/ml and approximately 30 mg/ml in DMSO and DMF. Description Epipregnanolone is a neurosteroid and an active metabolite of the steroid hormone pregnenolone (Item No. 19864).1 It is enzymatically formed from prognenolone via the intermediates progesterone (Item No. 15876) and 5β-dihydroprogesterone in the placenta.2 Epipregnanolone inhibits spontaneous 3 contractions in myometrial strips isolated from at-term pregnant women (IC50 = 156 µM). Epipregnanolone (10 and 20 mg/kg) decreases operant alcohol self-administration in rats.4 Maternal plasma levels of epipregnanolone increase over the duration of pregnancy. References 1. Prince, R.J. and Simmonds, M.A. 5β-pregnan-3β-ol-20-one, a specific antagonist at the neurosteroid site of the GABAA receptor-complex. Neurosci. Lett. 135(2), 273-275 (1992). 2. Hill, M., Cibula, D., Havlíkova, H., et al. Circulating levels of pregnanolone isomers during the third trimester of human pregnancy.
    [Show full text]
  • Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Changes to Astrocyte Structure and Function" (2020)
    University of Kentucky UKnowledge Theses and Dissertations--Medical Sciences Medical Sciences 2020 Involvement of the Sigma-1 Receptor in Methamphetamine- Mediated Changes to Astrocyte Structure and Function Richik Neogi University of Kentucky, [email protected] Author ORCID Identifier: https://orcid.org/0000-0002-8716-8812 Digital Object Identifier: https://doi.org/10.13023/etd.2020.363 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Neogi, Richik, "Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Changes to Astrocyte Structure and Function" (2020). Theses and Dissertations--Medical Sciences. 12. https://uknowledge.uky.edu/medsci_etds/12 This Master's Thesis is brought to you for free and open access by the Medical Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Medical Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • Sigma-1 Receptor Engages an Anti-Inflammatory and Antioxidant
    antioxidants Article Sigma-1 Receptor Engages an Anti-Inflammatory and Antioxidant Feedback Loop Mediated by Peroxiredoxin in Experimental Colitis Nikoletta Almási 1, Szilvia Török 1, Zsuzsanna Valkusz 2,Máté Tajti 2, Ákos Csonka 3, Zsolt Murlasits 4, Anikó Pósa 1,5, Csaba Varga 1 and Krisztina Kupai 1,2,* 1 Department of Physiology, Anatomy and Neuroscience, University of Szeged, H-6726 Szeged, Hungary; [email protected] (N.A.); [email protected] (S.T.); [email protected] (A.P.); [email protected] (C.V.) 2 Department of Medicine, Medical Faculty, Albert Szent-Györgyi Clinical Center, University of Szeged, H-6720 Szeged, Hungary; [email protected] (Z.V.); [email protected] (M.T.) 3 Department of Traumatology, University of Szeged, H-6725 Szeged, Hungary; [email protected] 4 Laboratory Animals Research Center, Qatar University, Doha 2713, Qatar; [email protected] 5 Interdisciplinary Excellence Center, University of Szeged, H-6726 Szeged, Hungary * Correspondence: [email protected]; Tel.: +36-6254-4884 Received: 9 October 2020; Accepted: 2 November 2020; Published: 4 November 2020 Abstract: Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition of the gastrointestinal tract. Since the treatment of IBD is still an unresolved issue, we designed our study to investigate the effect of a novel therapeutic target, sigma-1 receptor (σ1R), considering its ability to activate antioxidant molecules. As a model, 2,4,6-trinitrobenzenesulfonic acid (TNBS) was used to induce colitis in Wistar–Harlan male rats.
    [Show full text]
  • N,N-Dimethyltryptamine Compound Found in the Hallucinogenic Tea Ayahuasca, Regulates Adult Neurogenesis in Vitro and in Vivo Jose A
    Morales-Garcia et al. Translational Psychiatry (2020) 10:331 https://doi.org/10.1038/s41398-020-01011-0 Translational Psychiatry ARTICLE Open Access N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo Jose A. Morales-Garcia 1,2,3,4, Javier Calleja-Conde 5, Jose A. Lopez-Moreno 5, Sandra Alonso-Gil1,2, Marina Sanz-SanCristobal1,2, Jordi Riba6 and Ana Perez-Castillo 1,2,4 Abstract N,N-dimethyltryptamine (DMT) is a component of the ayahuasca brew traditionally used for ritual and therapeutic purposes across several South American countries. Here, we have examined, in vitro and vivo, the potential neurogenic effect of DMT. Our results demonstrate that DMT administration activates the main adult neurogenic niche, the subgranular zone of the dentate gyrus of the hippocampus, promoting newly generated neurons in the granular zone. Moreover, these mice performed better, compared to control non-treated animals, in memory tests, which suggest a functional relevance for the DMT-induced new production of neurons in the hippocampus. Interestingly, the neurogenic effect of DMT appears to involve signaling via sigma-1 receptor (S1R) activation since S1R antagonist blocked the neurogenic effect. Taken together, our results demonstrate that DMT treatment activates the subgranular neurogenic niche regulating the proliferation of neural stem cells, the migration of neuroblasts, and promoting the generation of new neurons in the hippocampus, therefore enhancing adult neurogenesis and
    [Show full text]